Juan Andres - 29 Oct 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
29 Oct 2021
Transactions value $
-$3,275,350
Form type
4
Filing time
02 Nov 2021, 16:16:18 UTC
Previous filing
29 Oct 2021
Next filing
05 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K 29 Oct 2021 Direct F1
transaction MRNA Common Stock Sale -$1.72M -5K -100% $344.49 0 29 Oct 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K 01 Nov 2021 Direct F1
transaction MRNA Common Stock Sale -$1.68M -5K -100% $335.00 0 01 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -3.57% $0.00 135K 29 Oct 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -3.7% $0.00 130K 01 Nov 2021 Common Stock 5K $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 This option is fully vested and exercisable.

Remarks:

Chief Technical Operations and Quality Officer